Table 1 Baseline characteristics of patients received neoadjuvant Afatinib therapy (n = 47)
From: Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
Variables | No. of patient (%) |
|---|---|
Age, years (range) | 60.6 (33–78) |
Gender | |
Male | 21 (44.7) |
Female | 26 (55.3) |
ECOG performance status | |
0 | 29 (61.7) |
1 | 18 (38.3) |
EGFR mutation | |
Ex19Del | 28 (59.6) |
L858R | 16 (34.0) |
G719X | 2 (4.3) |
S768I | 1 (2.1) |
Smoking status | |
Ever | 11 (23.4) |
Never | 36 (76.6) |
MTD at diagnosis, mm (range) | 43.2 (18–93) |
N Stage at diagnosis | |
0 | 0 (0.0) |
1 | 5 (10.6) |
2 | 32 (68.1) |
3 | 10 (21.3) |
cTNM stage at diagnosis | |
IIIA | 26 (55.3) |
IIIB | 18 (38.3) |
IIIC | 3 (6.4) |
Operable evaluation at diagnosis | |
Resectable | 22 (46.8) |
Potentially resectable | 25 (53.2) |
